About us
Welcome!
The
Company
Core
Technology
Welcome!
Especially
in the biotech industry, being first makes all the difference. We have
discovered the 'smart carriers' that can cross intact skin and other semi-permeable
barriers to transport effectively a wide variety of drugs into the body.
Our leadership in the design of self-regulating carrier systems puts
us in a position to develop prototypes rapidly and to focus quickly on
the best product candidates. Extensive in vivo studies have shown
the effectiveness of our proprietary drug delivery technology.
The basis of
's
proprietary technology is a bio-compatible, highly deformable and self-regulating,
water based agent carrier called Transfersome®.
The Company developed new product candidates based on such
carriers of whom several are in the clinic; the current focus is on dermatological
and pain therapeutics. IDEA is testing in the clinic Transfersome®
formulations for the targeted transdermal delivery of steroidal or nonsteroidal
anti-inflammatory drugs (NSAID) for improved safety and higher specificity
through Transfersome® mediated delivery. IDEA is also exploring the
development of transdermally delivered protein therapeutics as well as
transnasal / transdermal vaccination.
The Company
is a product-oriented company, founded in 1993 by Prof. Dr. Gregor Cevc
from the Technical University of Munich, following his invention of an
ultradeformable vesicle (Transfersome®), and the demonstration of
its unique drug transporting capabilities. The Company is located in the
Munich Technology Centre and employs around 45 highly motivated and skilled
people from different nationalities.
is backed by top-tier European and US investors.
Core Technology
Unlike
conventional transdermal technologies which disrupt the skin barrier to
enable drug passage through the skin
's
proprietary drug carriers (Transfersomes®) activate the natural, but
normally closed, pathways through the barrier. This only happens for a
selected period of time and does not compromise the protective properties
of the organ. It is therefore possible to transport various agents either
into the skin or through the skin into underlying tissues or the whole
body. This offers ample opportunities for pharmaceutical product development
and improvement.
permanently works on widening and strengthening the scientific basis of
its technology. The Company also continuously generates new applications
in the field of drug delivery. This includes strategies for improved drug-carrier-association,
for better temporal control of drug release and vaccine application, amongst
others. The Company has built-up a strong intellectual property base for
its technology platform.
<---- |
Home |
About us |
Corporate Factsheet |
Science |
Publications |
Product opportunities |
Finance |
Press releases |
Latest newsletter |
Press clippings |
Conferences |
Career |
Contact |
Scientific FAQ |
Glossary |
Site Map |
Search |